Navigation Links
Rib-X Pharmaceuticals Enters into Collaborative Agreement on Delafloxacin with Massachusetts General Hospital
Date:12/15/2009

SI). Delafloxacin successfully completed two additional Phase 2 trials with the oral formulation. In microbiological tests of large numbers of contemporary clinical isolates of quinolone resistant MRSA, delafloxacin has been shown to be at least 32-fold more potent than levofloxacin, ciprofloxacin, gatifloxacin and moxifloxacin. Delafloxacin also has been shown to be more potent than existing quinolones against a range of Gram-positive, anaerobic, and Gram-negative organisms. Rib-X is currently developing both IV and oral formulations of delafloxacin for use in surgical prophylaxis and other therapeutic areas.

About Rib-X Pharmaceuticals, Inc.

Rib-X Pharmaceuticals, Inc. is a product-driven small molecule drug discovery and development company focused on the structure-based design of new classes of antibiotics. The Company currently has two drug candidates: delafloxacin, which is ready to enter Phase 3 clinical trials, and radezolid, whose oral form has been tested for safety and efficacy in two Phase 2 trials. Delafloxacin is a broad-spectrum fluoroquinolone with potent activity against quinolone-resistant Gram-positive bacteria, including methicillin-resistant S. aureus (MRSA). Radezolid, a new oxazolidione discovered by Rib-X using its structure-based drug design approach, is an oral/IV agent for the treatment of serious multi-drug-resistant infections. The Company also has two other structure-based discovery programs, Rx-04 and Rx-02. The Rch-04 discovery program is developing novel classes of antibiotics active against multi-drug resistant Gram-negative bacteria. The Rx-02 discovery program is focused on developing an IV/oral macrolide active against MRSA, multidrug-resistant Streptococcus pneumoniae, and S. pyogenes. Rib-X's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in protein synthesis. Many know
'/>"/>

SOURCE Rib-X Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology
2. Rib-X Pharmaceuticals, Inc. Co-Founder, Thomas A. Steitz, Ph.D., Awarded the 2009 Nobel Prize in Chemistry
3. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
4. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
5. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
6. Rib-X Pharmaceuticals, Inc. Announces Recent and Upcoming Presentations at Scientific Conferences
7. Rib-X Pharmaceuticals Initiates Phase 2 Trial for RX-3341 In Complicated Skin and Skin Structure Infections
8. Rib-X Pharmaceuticals Renews Collaborative Agreement with the Medical Research Council
9. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
10. Transcept Pharmaceuticals Receives Notice of Allowance for Second U.S. Patent Application Covering Intermezzo(R)
11. Vion Pharmaceuticals Receives Complete Response Letter for Onrigin(TM) From The U.S. Food And Drug Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a multivariate ... has appointed Holly B. Bauzon as Vice ... Bauzon has a proven track record in both increasing ... companies. She has more than 20 years of healthcare ... the position of Director, Lab Services Sales and Managed ...
(Date:8/21/2014)...  eRelevance Corporation ( www.erelevancecorp.com ), a progressive ... has completed integration with Nextech, a popular Electronic ... Dermatology practices. "Integration allows our service ... using Nextech," stated Bob Fabbio , co-founder ... the EMR we are able to automatically target ...
(Date:8/21/2014)... NEW YORK , Aug. 21, 2014  Publicis ... Shannon Hartley , Managing Partner and Healthcare Industry ... of PharmaVoice 100, which recognizes the most inspiring people ... group are leaders in research and development, marketing, technology, ... the agency in 2006 as a partner in its ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Shannon Hartley Shines in PharmaVOICE 100 2
... The AXA Research Fund closed out its first year ... than Euro 13 million to various European research institutions.The purpose ... of major risks in the world by supporting cutting edge ... Euro 100 million over five years, making it a major ...
... Research features from Mayo ClinicROCHESTER, Minn., March 23 ... of Discovery,s Edge, Mayo Clinic,s research magazine. You ... often as you wish. Reprinting is allowed with ... as your editorial policies permit: Visit http://discoverysedge.mayo.edu ...
Cached Medicine Technology:First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 2First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 3Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu 2
(Date:8/21/2014)... 2014 Florida Hospital Zephyrhills is ... of the only in the Tampa Bay area ... the Olympus Endoalpha Universal Platform for surgical endoscopy. ... endoscopic specialties, and provides the hospital a standardized ... efficiencies and patient care. Surgical endoscopy systems, through ...
(Date:8/21/2014)... NY (PRWEB) August 21, 2014 Local ... often have larger discounts for specific protection plans, according ... now helping consumers to quote life insurance from local ... , The local agents that appear inside of the ... a fast method of price reviews this year. Adults ...
(Date:8/21/2014)... August 11: – Robin William’s suicide was ... hanging, likely due to long-term depression. , ... Vocal Profiling investigator, appeared on the Joyce Riley Power ... hoping to help people understand why he chose not ... were proposed in terms of BioAcoustic Biology: Using vocal ...
(Date:8/21/2014)... The “Proteomics Market by Technology ... Surface Plasmon Resonance, X-ray Crystallography) - Instruments, Reagents ... and studies the major market drivers, restraints, and ... Rest of the World (RoW) , Browse 138 ... pages and in-depth TOC on “Proteomics Market by ...
(Date:8/21/2014)... 22, 2014 DoudouneCanadienneGoosePasCher.fr, one of the ... has recently unveiled its new selection of Trillium Parkas ... announced that all these fashionable and comfortable items are ... special offer will last until September 01. , ... the new Canada Goose Trillium Parkas for ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Zephyrhills is Elevating Healthcare by Offering the First Olympus Fully-Integrated HD Operating Room in Pasco County 2Health News:Florida Hospital Zephyrhills is Elevating Healthcare by Offering the First Olympus Fully-Integrated HD Operating Room in Pasco County 3Health News:Life Insurance from Local Agents Now Priced Nationally Through Complimentary Tool Online 2Health News:Robin Williams: What he could not bear to face 2Health News:Robin Williams: What he could not bear to face 3Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:Proteomics Market worth $20,696.4 Million by 2018 - New Research Report by MarketsandMarkets 5Health News:Fashionable And Comfortable Canada Goose Trillium Parkas For Sale At DoudouneCanadienneGoosePasCher.fr 2
... ... 2009. , ... October 16, 2009 -- Tony Rico has recently been promoted to Senior Vice President of ... promotion was effective September 1, 2009. , , , , ,"This position has ...
... A bioethicist who specializes in moral dilemmas families face ... honored with the first-ever March of Dimes Distinguished Lectureship ... a nationally-recognized pediatrician and ethicist, will deliver his lecture ... the American Society of Bioethics and Humanities, 11th annual ...
... Feature Gena Rowlands , EAST BRUNSWICK, N.J., Oct. 15 ... home to New Jersey to host a celebrity cocktail reception ... will raise money for National MS Society,s New Jersey Metro ... Jersey, where it is estimated that almost 10,000 people have ...
... 15 ResMed Inc. (NYSE: RMD ), announced today that ... the first quarter of fiscal year 2010, ended September 30, 2009. ... p.m. Pacific Time and the Company will host a conference call ... , The conference call is scheduled to begin at 1:30 p.m. ...
... AUSTIN, Texas, Oct. 15 deverus, inc., a ... for background screening companies, announced today that Corporate ... deverus, Verocity 2009 software platform to provide an ... An affiliate of Corporate Research and Investigations (Pvt.) ...
... WASHINGTON, Oct. 15 A National Awareness Campaign to ... Arabia to coincide with international Breast Cancer Awareness month. The campaign ... of the Zahra Breast Cancer Association and wife of the ... , and Princess Rima bint Abdullah bin Abdulaziz. It officially ...
Cached Medicine News:Health News:Jackson & Coker Promotes Tony Rico to Senior VP of Operations 2Health News:March of Dimes Establishes Two New Perinatal Bioethics Awards 2Health News:March of Dimes Establishes Two New Perinatal Bioethics Awards 3Health News:East Brunswick Native Returns Home to Help New Jersey Residents Living with MS 2Health News:ResMed Announces Conference Call and Webcast to Discuss First Quarter 2010 Results 2Health News:deverus(TM) Expands Operations Overseas 2
... Plus Povidone Iodine (PVP-I) Prep ... a 10% Povidone Iodine, USP ... Iodine. Triad Plus Povidone Iodine ... saturated with a 7.5% Povidone ...
Prevail is a fast-acting, effective antimicrobial gel that makes preoperative preps easier. This unique gel formulation comes in a specifically designed, easy to use applicator for excellent flow con...
The new, single-use 26 mL applicator is latex-free, hands-off and sterile to help prevent cross-contamination. The applicator is designed for a smooth delivery of the solution for larger surgical pro...
These simple but effective single-dose, hands-off, ampulized applicators have revolutionized skin preparation in hospitals....
Medicine Products: